Zacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of “Strong Buy” from Brokerages

Denali Therapeutics Inc (NASDAQ:DNLI) has received an average broker rating score of 1.17 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.

Brokers have set a twelve-month consensus price objective of $24.67 for the company and are expecting that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Denali Therapeutics an industry rank of 193 out of 265 based on the ratings given to related companies.

A number of analysts have weighed in on the company. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a research report on Tuesday, January 2nd. They issued an “overweight” rating and a $24.00 price target for the company. Goldman Sachs Group assumed coverage on Denali Therapeutics in a research report on Tuesday, January 2nd. They issued a “neutral” rating for the company. Evercore ISI assumed coverage on Denali Therapeutics in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $23.00 price target for the company. Finally, Morgan Stanley assumed coverage on Denali Therapeutics in a research report on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 price target for the company.

In other Denali Therapeutics news, major shareholder Douglas K. Bratton acquired 275,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was acquired at an average price of $18.00 per share, with a total value of $4,950,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Several hedge funds and other institutional investors have recently bought and sold shares of DNLI. Artal Group S.A. acquired a new position in shares of Denali Therapeutics during the 4th quarter worth about $7,820,000. NF Trinity Capital Hong Kong Ltd acquired a new position in shares of Denali Therapeutics during the 4th quarter worth about $1,564,000. Wells Fargo & Company MN acquired a new position in shares of Denali Therapeutics during the 4th quarter worth about $621,000. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Denali Therapeutics during the 4th quarter worth about $237,000. 0.06% of the stock is owned by institutional investors and hedge funds.

Shares of Denali Therapeutics (NASDAQ:DNLI) traded down $0.27 during trading hours on Monday, hitting $21.22. The company’s stock had a trading volume of 100,358 shares, compared to its average volume of 309,047. Denali Therapeutics has a 12 month low of $14.72 and a 12 month high of $24.02.

ILLEGAL ACTIVITY WARNING: “Zacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of “Strong Buy” from Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/12/zacks-denali-therapeutics-inc-dnli-receives-consensus-recommendation-of-strong-buy-from-brokerages.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply